Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYES
Previous Symbol
CUSIPN/A
Phone818-833-5000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.37
Quick Ratio0.89
Price-To-Earnings
Trailing P/E Ratio-2.17
Forward P/E Ratio-2.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.96 million
Price / Sales11.06
Cash FlowN/A
Price / CashN/A
Book Value$0.05 per share
Price / Book24.20
Profitability
EPS (Most Recent Fiscal Year)($0.59)
Net Income$-28,510,000.00
Net Margins-408.41%
Return on Equity-638.26%
Return on Assets-279.24%
Miscellaneous
Employees112
Outstanding Shares72,780,000
Market Cap$106.26 million
OptionableOptionable
Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions
What is Second Sight Medical Products' stock symbol?
Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."
How were Second Sight Medical Products' earnings last quarter?
Second Sight Medical Products Inc (NASDAQ:EYES) posted its quarterly earnings results on Wednesday, November, 7th. The medical device company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. The medical device company earned $2.25 million during the quarter, compared to analysts' expectations of $2.48 million. Second Sight Medical Products had a negative return on equity of 638.26% and a negative net margin of 408.41%. View Second Sight Medical Products' Earnings History.
When is Second Sight Medical Products' next earnings date?
What price target have analysts set for EYES?
1 brokerages have issued 1-year price objectives for Second Sight Medical Products' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 313.2% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.
What is the consensus analysts' recommendation for Second Sight Medical Products?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.
Has Second Sight Medical Products been receiving favorable news coverage?
News coverage about EYES stock has trended positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Second Sight Medical Products earned a news sentiment score of 2.2 on InfoTrie's scale. They also assigned news headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Second Sight Medical Products' key competitors?
Some companies that are related to Second Sight Medical Products include Cutera (CUTR), Rockwell Medical (RMTI), BioLife Solutions (BLFS), Electrocore (ECOR), Semler Scientific (SMLR), Fonar (FONR), Zynex (ZYXI), Stereotaxis (STXS), Edap Tms (EDAP), IRIDEX (IRIX), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Digirad (DRAD), ENDRA Life Sciences (NDRA) and Aradigm (ARDM).
Who are Second Sight Medical Products' key executives?
Second Sight Medical Products' management team includes the folowing people:
- Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 55)
- Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 54)
- Gunnar Bjorg, Founder
- Mr. John T. Blake, CFO & Corp. Sec. (Age 42)
- Mr. William Patrick Ryan, Chief Operating Officer (Age 57)
When did Second Sight Medical Products IPO?
(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.
How do I buy shares of Second Sight Medical Products?
Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Second Sight Medical Products' stock price today?
One share of EYES stock can currently be purchased for approximately $1.21.
How big of a company is Second Sight Medical Products?
Second Sight Medical Products has a market capitalization of $106.26 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe.
What is Second Sight Medical Products' official website?
How can I contact Second Sight Medical Products?
Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD BLDG. 3, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]
MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
